Literature DB >> 19934177

Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?

D Erkan1, M Barbhaiya, D George, L Sammaritano, Md Lockshin.   

Abstract

The association between antiphospholipid antibodies (aPL) and clinical events is stronger with a positive lupus anticoagulant (LA) test, higher anticardiolipin antibody (aCL) titers, and/or higher anti-beta(2)-glycoprotein-I antibody (abeta( 2)GPI) titers. The objective of this study was to determine the clinical characteristics of persistently high-titer (> or =80 U) aCL-positive patients compared with those with persistent moderate aCL titers (40-79 U). Second, we analyzed whether high-titer abeta(2)GPI test adds predictive information in persistently moderate-to-high titer aCL-positive patients. In this cross-sectional study, the primary analysis compared the clinical and aPL characteristics of 58 patients with at least two moderate-titer aCL results to another 85 patients with at least two high-titer aCL results. In the secondary analysis of patients with at least two abeta(2)GPI test results, we compared 29 patients with 'aCL 40-79 U and abeta( 2)GPI < 80 U' profiles with 8 patients with 'aCL 40-79U and abeta(2)GPI > or = 80 U', and also compared 27 patients with 'aCL > 80 U and abeta(2)GPI < 80 U' with 32 patients with 'aCL > 80 U and abeta(2)GPI > or = 80 U'. Although aPL-related vascular and pregnancy events were similar between the moderate- and high-titer aCL groups, the number of patients with positive LA tests (RR 2.06, CI 1.38-3.08, p < 0.01) and with at least one non-criteria aPL manifestation (RR 1.66, CI 1.20-2.30, p = 0.0005) were significantly higher in the high-titer aCL group. While magnetic resonance imaging (MRI) white matter changes were statistically more common in the high-titer aCL group (RR 2.03, CI 1.04-3.94, p = 0.02), there was a trend towards increased prevalence of livedo reticularis, cardiac valve disease, and cognitive dysfunction occurring in the high-titer aCL group. The secondary analysis showed that MRI white matter changes, cardiac valve disease, and cognitive dysfunction were proportionally more common in the high-titer abeta( 2)GPI groups, suggesting a linear relationship between non-criteria aPL manifestations and aPL titers. Our results suggest that patients with high aCL titers, compared with those with moderate titers, are more likely to have a positive LA test and a higher prevalence of non-criteria aPL manifestations. Furthermore, high-titer abeta(2)GPI positivity may further increase the prevalence of non-criteria aPL manifestations in moderate- or high-titer aCL-positive patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934177     DOI: 10.1177/0961203309355300

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Authors:  Michael D Lockshin; Mimi Kim; Carl A Laskin; Marta Guerra; D Ware Branch; Joan Merrill; Michelle Petri; T Flint Porter; Lisa Sammaritano; Mary D Stephenson; Jill Buyon; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2012-07

2.  APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.

Authors:  Brenda B Suh-Lailam; Anndorie Cromar; K Wayne Davis; Anne E Tebo
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

3.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 4.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 5.  Antiphospholipid syndrome and the brain in pediatric and adult patients.

Authors:  E Muscal; R L Brey
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

6.  Are posttranslational modifications of β2-glycoprotein I markers for thrombotic risk? Are they triggers of autoimmunity?

Authors:  Michael D Lockshin; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2011-09

7.  Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Sandra Djokic; Branka Filipovic; Predrag Matic; Milomir Milanovic; Svetlana Apostolovic; Jovica Saponjski
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

8.  Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity.

Authors:  Jung Yoon Pyo; Seung Min Jung; Sang Won Lee; Jason Jungsik Song; Soo Kon Lee; Yong Beom Park
Journal:  Yonsei Med J       Date:  2017-11       Impact factor: 2.759

Review 9.  Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Authors:  Miguel Leal Rato; Matilde Bandeira; Vasco C Romão; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-14       Impact factor: 5.081

10.  Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.

Authors:  Claire Donnellan; Hannah Cohen; David J Werring
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.